Literature DB >> 9176403

Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities.

K Hida1, M Shindoh, M Yasuda, M Hanzawa, K Funaoka, T Kohgo, A Amemiya, Y Totsuka, K Yoshida, K Fujinaga.   

Abstract

E1AF is a newly identified human ets-family transcription factor. We have reported that E1AF can up-regulate transcription of matrix metalloproteinase (MMP) genes and confers invasive phenotype on human cancer cells. HSC3 is an oral squamous-cell-carcinoma-derived cell line, and it manifests high levels of E1AF and MMP-1 and -9 gene expression that are associated with invasive potential. We reconstructed an E1AF antisense expression vector, transfected HSC3 cells with the vector, and obtained HSC3AS cells that express E1AF antisense RNA. HSC3AS showed decreasing mRNA and protein levels of MMP-1, -3, and -9. Moreover, HSC3AS showed lower invasive potential in vitro three-dimensional raft culture and in vivo implantation into nude mice. These results imply that transfection of antisense E1AF inhibits tumor invasion by down-regulating MMP genes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176403      PMCID: PMC1858336     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells.

Authors:  J H Xin; A Cowie; P Lachance; J A Hassell
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

Review 2.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

Review 3.  The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas.

Authors:  L M Matrisian; S McDonnell; D B Miller; M Navre; E A Seftor; M J Hendrix
Journal:  Am J Med Sci       Date:  1991-09       Impact factor: 2.378

Review 4.  Cancer invasion and metastasis: positive and negative regulatory elements.

Authors:  L A Liotta; W G Stetler-Stevenson; P S Steeg
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

Review 5.  The Ets family of transcription factors.

Authors:  B Wasylyk; S L Hahn; A Giovane
Journal:  Eur J Biochem       Date:  1993-01-15

Review 6.  Tumor invasion and metastasis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; W G Stetler-Stevenson
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

7.  Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy.

Authors:  Y Kaneko; K Yoshida; M Handa; Y Toyoda; H Nishihira; Y Tanaka; Y Sasaki; S Ishida; F Higashino; K Fujinaga
Journal:  Genes Chromosomes Cancer       Date:  1996-02       Impact factor: 5.006

8.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.

Authors:  H Sato; M Seiki
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

9.  The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins.

Authors:  C Wasylyk; A Gutman; R Nicholson; B Wasylyk
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

10.  PEA3 is a nuclear target for transcription activation by non-nuclear oncogenes.

Authors:  C Wasylyk; P Flores; A Gutman; B Wasylyk
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

View more
  9 in total

Review 1.  Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis.

Authors:  Natasza A Kurpios; Nancy A Sabolic; Trevor G Shepherd; Gina M Fidalgo; John A Hassell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

Review 2.  Role of Ets transcription factors in mammary gland development and oncogenesis.

Authors:  T Shepherd; J A Hassell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

3.  nm23-H1 suppresses invasion of oral squamous cell carcinoma-derived cell lines without modifying matrix metalloproteinase-2 and matrix metalloproteinase-9 expression.

Authors:  M H Khan; M Yasuda; F Higashino; S Haque; T Kohgo; M Nakamura; M Shindoh
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

4.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  ATXN1 protein family and CIC regulate extracellular matrix remodeling and lung alveolarization.

Authors:  Yoontae Lee; John D Fryer; Hyojin Kang; Juan Crespo-Barreto; Aaron B Bowman; Yan Gao; Juliette J Kahle; Jeong Soo Hong; Farrah Kheradmand; Harry T Orr; Milton J Finegold; Huda Y Zoghbi
Journal:  Dev Cell       Date:  2011-10-18       Impact factor: 12.270

6.  NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.

Authors:  Anthony G Clementz; Allison Rogowski; Kinnari Pandya; Lucio Miele; Clodia Osipo
Journal:  Breast Cancer Res       Date:  2011-06-14       Impact factor: 6.466

7.  Pea3 transcription factors and wnt1-induced mouse mammary neoplasia.

Authors:  Rebecca Baker; Claire V Kent; Rachel A Silbermann; John A Hassell; Lawrence J T Young; Louise R Howe
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

8.  Progress in the molecular biology of ewing tumors.

Authors:  H Kovar
Journal:  Sarcoma       Date:  1998

9.  Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter.

Authors:  U Benbow; J L Rutter; C H Lowrey; C E Brinckerhoff
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.